How Much Equity Should Biotech Founders Give Investors?

The honest short answer: as little as you can while still raising what you actually need. That is true, and it is also useless on its own, because it gives you no numbers, no benchmarks, and no way to tell a fair deal from a bad one. The useful answer requires three things most founders never line up together. The per-round benchmarks for what is normal. The cumulative math that shows where your ownership really goes across a full decade of financing. And the hidden mechanics that quietly take more than the headline number suggests.

Founders fixate on the one figure an investor quotes (“we want 20%”) and miss the option pool, the SAFE conversions, the pro rata rights, and the liquidation preferences that do the rest of the damage.

Biotech makes all of this harder for one structural reason: you will raise more rounds over more years than a software company, so dilution compounds further before you reach a liquidity event. Getting the equity question right is not a nice-to-have. It is the difference between owning a meaningful slice of a big outcome and wondering where your company went.

This guide: How Much Equity Should Biotech Founders Give Investors gives you the numbers, the math, the traps, the biotech-specific levers, and a twelve-month plan to put them to work.

Why Biotech Dilution Is Different From Tech Startup Dilution

Three structural realities separate biotech dilution from what generic startup equity guides describe, and each one compounds the consequence of getting any single round wrong.

The timeline

A software company can go from seed to exit in five to seven years. A therapeutic program often takes a decade or more to reach commercialization, and capital can only compress that timeline so far before regulatory and biological realities reassert themselves. A founder who raises aggressively at seed may face six, seven, or eight rounds of dilution before a meaningful liquidity event. Give up roughly 20% per round across that many events and the compounding effect is severe.

The capital intensity

Bringing a single therapeutic from discovery to approval is widely estimated to cost in the billions of dollars across the full development arc. Even when non-dilutive capital bridges the earliest science, biotech founders face materially larger and more numerous equity rounds than software founders, whose product can be iterated and shipped without a regulator in the loop.

The milestone dependency

Biotech valuations move on clinical and regulatory milestones, not on revenue. That makes the valuation step-up between rounds far less predictable than in SaaS, where steady revenue growth feeds a reliable valuation formula. When a clinical milestone slips, and they frequently do, the next round can close flat or down, diluting founders without the compensating benefit of a higher pre-money. The result is dilution that does not feel like progress, because it is not.

Put together, these three factors mean every dilution decision a biotech founder makes carries more cumulative consequence than the same decision in almost any other sector. Modeling the full path before signing the first term sheet is not optional. It is the foundational financial discipline of building a biotech company.

The real goal: own enough of a big enough outcome

Here is the single most important reframe before we get to numbers. The objective is not to own the largest percentage. It is to own enough of a large enough outcome.

A founder who owns 20% of a company that exits for $500 million did far better than one who clung to 60% of a company that stalled at $20 million for lack of capital. Dilution only hurts when the money you raised failed to grow the company’s value faster than it shrank your slice. Judge every round by that test, not by the percentage alone.

Biotech Founder Dilution Benchmarks by Stage: What the 2026 Data Shows

The most reliable primary source for startup dilution benchmarks is Carta, drawn from tens of thousands of real cap tables on its platform. Treat the numbers below as reference points. Your actual figures depend on valuation, leverage, how much you raise, and what investors expect to see at each funding stage.

The working rule of thumb

For a single priced round in the early stages, the benchmark is 15% to 25% to investors, with roughly 20% as the typical center of gravity. That is the slice the new investors buy. It is not the slice you lose, because option pools and conversions add to the total. That gap between the headline and the real number is the first thing the simple rule hides.

Pre-seed and seed

• Pre-seed gives up a smaller slice, often in the low-to-mid teens, and almost always on convertible instruments rather than priced equity. The post-money SAFE with a valuation cap and no discount has become the standard pre-seed instrument, used in the large majority of rounds, with pre-money SAFEs now effectively legacy. For a raise in the $1 million to $1.9 million range, median expected dilution runs around 15% to 16%, climbing past 23% as round sizes approach $5 million and up.
• Seed rounds cluster near 20%. Founders typically sell about a fifth of the company in a priced seed.
• The median seed post-money valuation has been climbing. Carta data put the median seed post-money valuation at a record $24 million in late 2025, with Series A reaching $78.7 million. Higher pre-money valuations are exactly what let you raise the same dollars for less ownership.
• Add the option pool on top, and founders commonly exit the seed round owning somewhere in the 60% to 70% range collectively.

Series A and the 50% threshold

• Series A again centers near 20% to the new investors, plus an option-pool refresh.
• A widely used guardrail: investors generally want the founding team to still hold at least 50% after Series A. Ownership below that can sap founder motivation and signal trouble to the next investor.
• In practice, biotech founding teams often land below that line once the pool refresh is included, which is exactly why the earlier rounds need discipline, and why it pays to understand what it takes to clear the Series A bar on valuation and process well before you get there.

Series B and beyond

• Per-round dilution typically narrows at later stages, to roughly 15% to 18% at Series B and lower thereafter, as clinical de-risking lifts pre-money valuations and the cap table thickens.
• The slices get smaller in percentage terms, but they stack on an already-diluted base. A 15% round when you own 35% costs you more of what remains than the same 15% did at the start.

The over-dilution warning signs

Some numbers are red flags that you are giving away too much, too early:

• Giving away more than 25% in a single seed round, or 40% to 60% cumulatively before Series A, signals business-model problems to sophisticated investors.
• Splitting small stakes among too many investors, which clutters the cap table without strategic benefit.

If your plan has you crossing these lines, the cause is usually that you are raising too much at too low a valuation, not that the market demands it.

What Founder Ownership Actually Looks Like After Each Round

Per-round benchmarks tell you what you give up at each event. The cumulative trajectory tells you what you actually own at the end of each one, and that is the picture most founders fail to model until it is too late to adjust.

The founder-ownership trajectory

The authoritative picture, drawn from real cap tables: the median founding team retains about 56% of fully diluted equity after seed, 36% after Series A, and 23% after Series B, with employee ownership surpassing founder ownership by Series C. At Series C, the median founder holds 16.1%, just below the 16.8% held collectively by the employees they hired.

Read that trajectory carefully. Founders are giving up roughly 20 percentage points of the company in each of the first couple of rounds, the steepest decline happens early, and investors cross the 50% ownership threshold somewhere between Series A and Series B.

Biotech sits on the harder side of this. Founders in physical and non-AI sectors keep less of their equity than software and AI founders at the same stage. At Series A, founders in digital industries retain a median of 37.5%, while founders in physical industries retain just 30.5%.

The differential reflects both the capital intensity of the sector and the longer gaps between milestones that slow valuation appreciation between rounds.

A worked biotech cap table example

A simplified, illustrative path from incorporation through Series B. The exact figures shift with valuation and pool size, but the shape is universal.

• Incorporation: founders own 100%.
• Seed: investors take about 20%, and a roughly 10% option pool is created pre-money. Founders drop to around 70%.
• Series A: new investors take about 20%, and the term sheet requires refreshing the option pool. Founders land near 50%, often a bit below in biotech.
• Series B: another institutional slice plus a pool top-up pulls founders into the 30s.

The lesson sits in the structure, not the specific percentages: each round is the round itself plus a pool refresh, and both come out of your slice.

What founders typically retain at exit

A reasonable target to plan around is owning 15% to 25% as a founding team after Series B, which is enough to be life-changing at a strong exit while leaving room to raise again. Many biotech founders, after additional clinical-stage rounds, exit owning somewhere in the mid-teens to low-twenties as a team. That can still be an enormous outcome, if the company grew enough to justify every round.

This trajectory is not here to discourage. Ten percent of a company that exits at $2 billion is $200 million, a far better outcome than 100% of an unfunded hypothesis. The goal is not to minimize dilution in isolation. It is to understand the trajectory, model it from day one, and make every capital decision with the full picture visible.

The Cumulative Dilution Problem Most Biotech Founders Never Model

The most consequential mistake in biotech cap table management is not negotiating a single bad term sheet. It is failing to model the cumulative effect of every term sheet across the full funding arc before signing the first one.

A founder who models the trajectory at day one understands clearly that the seed round on the table today will compound into a Series A, a Series B, and a Series C before any liquidity event, and that roughly 20% dilution per round across five rounds leaves them owning about a third of what they started with, before the option pool is even factored in.

The practical implication: the size of the round, the pre-money valuation, and the amount of non-dilutive capital used to bridge each milestone are not independent decisions. They are three levers on the same compounding system. Founders who treat each raise as a standalone negotiation, and only look at per-round dilution, consistently underestimate how far their cumulative ownership will fall by exit.

The current market makes this worse. Roughly 15% of venture rounds in 2025 were completed at lower valuations, close to the decade high set in 2024, according to PitchBook. Down rounds are dangerous on their own, and they are doubly dangerous when paired with anti-dilution provisions, which we will get to below.

Build the full dilution model before you raise your first dollar. Every subsequent round is easier to navigate when you can see where it fits in a trajectory you have already mapped.

The Hidden Dilution Sources Most Biotech Founders Miss

The headline percentage is the part everyone sees. These five mechanics do quiet damage, and they are where biotech founders most often lose ownership they never budgeted for.

The option pool shuffle

In most term sheets, the employee option pool is required to be set, or expanded, based on a pre-money calculation. The pool is carved out of the pre-money valuation before new investor money comes in, which dilutes the existing shareholders, primarily the founders, before a single dollar of the new round has landed.

The effect is concrete. If you raise $15 million at a $45 million pre-money with a required 15% option pool, you are negotiating your dilution against the effective pre-money after the pool carve-out, not against the full $45 million on the term sheet. Your economic pre-money is lower than the stated pre-money by exactly the pool value.

Founders have two main tools here:

• Size the pool to a real hiring plan. A documented twelve-month hiring roadmap gives you a defensible basis for requesting a smaller pool than the investor’s round-number default.
• Push for a post-close pool, not pre-close. Setting the pool post-close spreads the dilution proportionally across all shareholders, including the new investor, rather than loading it entirely onto existing holders.

One more discipline matters: investors always negotiate on a fully diluted basis, accounting for all options, warrants, and convertibles when they calculate their ownership. Founders who track ownership on an undiluted basis until a round closes are systematically underestimating what they are giving up. Track on a fully diluted basis from the first SAFE forward.

SAFEs and convertible notes

These instruments defer the equity decision, but they do not avoid it. They create what practitioners call phantom equity: ownership you have already promised that does not appear on the cap table until a priced round triggers conversion.

The danger compounds when founders stack multiple SAFEs at different caps without modeling the combined conversion. Each pre-money SAFE converts against a different denominator depending on the order of conversion, which produces an arithmetic compounding effect that consistently leaves founders owning less at the priced round than they expected when each SAFE was signed.

When the hit lands, it lands on founders. Insisting on post-money SAFEs with a single clean cap and no discount removes most of these surprises.

Pro rata rights

Pro rata rights let existing investors maintain their percentage by buying into later rounds. When they exercise, the dilution that would have been spread across the cap table is absorbed disproportionately by those without such rights, including founders. Granting broad pro rata rights early can quietly concentrate ownership and reduce the room you have to bring in new strategic investors later.

Liquidation preferences

This is the mechanic that bites at the finish line rather than at signing. A liquidation preference pays investors back first, before the remaining proceeds are split among common shareholders. With a 1x preference, an investor who put in $10 million takes $10 million off the top.

The structure matters more than founders realize:

• Non-participating preferred forces the investor to choose: take the preference, or convert to common and take their ownership percentage, but not both. This is the founder-friendly standard.
• Participating preferred lets the investor take the preference and then share in the remaining proceeds. This double-dip can cost founders millions at a modest exit.

The good news is that the market standard is clean. In Cooley’s Q4 2025 venture financings, 98% of deals carried a 1x liquidation preference and 96% used non-participating preferred stock. The risk is in the exceptions: a 1.5x or 2x multiple, a participating structure, or stacked senior preferences across multiple rounds can quietly consume most of a middling exit.

Preferences bite hardest when the exit is small relative to capital raised, which matters in biotech, where acquisition values vary widely. At a $50 million exit with a 1x preference on $10 million invested, a founder who nominally owns 20% may receive meaningfully less than the $10 million the percentage implies, because the preference is paid before the split.

Anti-dilution provisions

Anti-dilution clauses reprice an earlier investor’s shares when a later round closes below the prior price. There are two flavors, and the difference is enormous in a down market:

• Full ratchet reprices the earlier shares as if they had been bought at the new, lower price, which can transfer 30% to 50% of ownership to earlier investors in a single down round.
• Broad-based weighted average adjusts the price only partially, in proportion to the size of the down round relative to the cap table. It is the founder-friendly standard and the one to insist on whenever full ratchet is proposed.

With down rounds near a decade high, understanding which anti-dilution provision sits in your term sheet is a material financial decision, not a legal formality.

Biotech-Specific Dilution Considerations

Beyond the mechanics that apply to all startups, biotech founders face three dynamics that generic equity guides do not address.

Corporate venture terms

Corporate venture arms from pharma and medtech often invest with strategic terms that go beyond what pure financial VCs request: rights of first negotiation on licensing, co-development rights, or extended information rights. These can constrain your strategic optionality in ways that affect exit valuation, which indirectly affects the real value of your remaining equity, even before any direct dilution math.

Milestone-based tranching

One of the most founder-friendly structures in biotech is a tranched round, where a larger total commitment is split into two or three tranches, each released on a specific preclinical or regulatory milestone. Tranching limits upfront dilution to what the first milestone justifies and preserves optionality on the rest until you have earned a higher valuation by de-risking the program.

This is not a fringe structure: the share of life sciences venture financings structured in tranches rose to about 28% in early 2026, up from roughly 24% the prior quarter, per Cooley. The trade-off is negotiation complexity and the risk that a missed milestone delays access to the later tranche.

Non-dilutive capital as a dilution shield

Every dollar of non-dilutive capital that funds a scientific milestone is a dollar that does not require giving up equity. A grant that funds the equivalent of a small seed round can preserve a meaningful chunk of founder ownership at the subsequent equity raise, because you reach the milestone that justifies a higher valuation without selling any stock to get there.

This is the single highest-leverage equity tool available to early-stage biotech founders, and it deserves its own section.

Non-Dilutive Capital: The Biotech Founder’s Most Underused Equity Shield

The most efficient equity protection tool is not sharper negotiation at seed. It is funding the maximum possible scientific progress before the first equity round, using capital that requires no ownership transfer at all.

SBIR and STTR grants

SBIR and STTR grants from the NIH, NSF, DoD, and other federal agencies are the largest single source of non-dilutive capital for early-stage health technology companies, and the NIH runs the biggest program of any agency. The NIH guideline for an SBIR or STTR Phase I award is about $323,000 over six months to two years, with Phase II awards around $2.15 million over one to three years, and no equity required. Individual institutes can set their own limits, and some waiver topics allow more.

A company that sequences a Phase I and a Phase II award before its first priced round can fund on the order of $2 million of preclinical work without giving up a single basis point of ownership. At a 20% seed dilution rate, that same $2 million raised as equity would have cost a meaningful slice of the company, depending on the pre-money.

(One planning note: federal SBIR and STTR authority lapsed briefly in late 2025 before being reauthorized through 2031, so confirm current solicitation status with the program officer before you build a timeline around it.)

Beyond SBIR

The broader non-dilutive landscape for biotech founders includes:

• NIH exploratory grants such as the R21 mechanism for early, higher-risk work.
• DoD CDMRP funding, which targets specific disease areas including cancer, traumatic brain injury, and rare diseases.
• Patient advocacy foundation programs. Organizations like the Michael J. Fox Foundation, the Cystic Fibrosis Foundation, and JDRF run grant or venture-style programs in their disease areas.
• FDA designations. Breakthrough Therapy and Breakthrough Device designations do not provide capital directly, but they compress the regulatory timeline in ways that lift pre-money valuation at the next round.

Venture debt

Venture debt is a later-stage non-dilutive tool that extends runway or funds interim milestones without triggering a new equity round. A facility taken alongside or between equity rounds carries interest and sometimes warrant coverage, but that warrant coverage is typically far less dilutive than a new priced round for the same capital.

For pre-seed and seed founders specifically, the sequencing decision between non-dilutive and dilutive capital is the highest-leverage equity choice you will make, and it matters most when you are raising before you have clinical data to show.

How to Negotiate Better Dilution Terms as a Biotech Founder

Understanding the benchmarks is necessary. Negotiating well within them is where the equity protection actually happens. Five levers are available at any stage.

Anchor your valuation to comparable deals

The most direct way to reduce dilution for a given raise is to raise it at a higher pre-money. The most defensible basis for a higher valuation is a recent comparable deal in your therapeutic area at a similar stage. Use PitchBook, Crunchbase, or a sector fundraising tracker to identify two or three comparable rounds, document the pre-money, round size, and lead investor for each, and present them. Investors negotiate on data. Meeting them with better data is the most reliable way to improve terms.

Choose a clean SAFE structure

If the round is on convertible instruments, insist on a post-money SAFE with a valuation cap and no discount. The post-money cap defines exactly what percentage the holder will own at conversion, which makes dilution calculable at signing rather than a compounding surprise at the priced round. Avoid stacking multiple SAFEs at mismatched caps.

Manage option pool size and timing

Size the pool to a documented hiring plan rather than a round-number percentage, and request that it be set post-close rather than pre-close. Together these two adjustments can shave several percentage points off your effective pre-round dilution, depending on the investor’s default ask.

Use milestone tranches

Structure larger rounds into tranches tied to objective milestones, such as an in vitro result, an IND filing, or a Phase I initiation, rather than accepting the full amount up front. Tranching limits upfront dilution to what the first milestone justifies and preserves the option to raise the rest at a higher valuation once the program is de-risked.

Raise from strength, at higher valuations

The cleanest path to a higher valuation is to raise from a position of strength: after a milestone, with multiple interested investors, and well before you run low on cash. Walk in with nine months of runway or less and investors will read the weakness in your terms. The dilution math reflects your leverage, so protect your leverage.

What Constitutes Bad Dilution in Biotech

Not all dilution is equal. These are the patterns that most damage founder ownership without commensurate benefit, and they are more common in biotech than founders realize before experiencing one.

• Pricing seed too low out of desperation. Accepting a $3 million to $4 million pre-money because you need cash quickly, when comparable companies have raised at $10 million to $15 million, gives up 30% to 40% of the company at a price you did not have to accept. This dilution is permanent and compounding.
• Bridge rounds at flat or down valuations. A bridge that closes at or below the prior round dilutes founders with no increase in what the company is worth, and it can trigger anti-dilution provisions that transfer still more ownership to earlier investors.
• Raising more than the milestone requires. A larger round is not always a better round. Capital raised beyond the next value-inflection milestone costs equity today but only creates value at the next, higher pre-money. Size rounds precisely to the next milestone, with a buffer for slippage.
• Setting the option pool too large too early. A 20% pool at seed, before a hiring plan justifies it, dilutes founders immediately and stockpiles unissued options that will absorb future hires without a fresh expansion. Size the pool to the next twelve to eighteen months of hires.

Common Dilution Mistakes Biotech Founders Make

• Not modeling cumulative dilution before the first round. The founders most surprised by their Series C ownership are those who only looked at per-round percentages and never built a single model that compounded them across the full arc.
• Skipping non-dilutive funding before the first equity round. SBIR grants, NIH funding, and accelerator capital are available to most early-stage biotech teams, yet many move straight to angel or seed equity before exhausting them. Every non-dilutive dollar spent before a priced round preserves equity at the exact point where the first dilution event would otherwise hit.
• Stacking pre-money SAFEs without modeling conversion. Pre-money SAFEs stacked on top of each other create compounding conversion surprises at the priced round. Each converts against a different denominator, and the arithmetic consistently leaves founders owning less than they expected.
• Ignoring anti-dilution provisions. Full ratchet provisions still appear in term sheets, and with down rounds near a decade high they carry real risk. Negotiate for broad-based weighted average whenever full ratchet is proposed.
• Accepting investor-defined option pool sizing without a hiring plan. The default pool request is designed to protect the investor’s post-round percentage, not to reflect what you need to hire. Without a specific plan to push back with, founders give up more to the pool than necessary.

Cap Table Discipline: Why Messy Cap Tables Kill Biotech Deals

A clean, well-modeled cap table is not housekeeping. It is a fundability requirement.

Model before you negotiate

Build your dilution waterfall across all planned rounds before you sit down with any investor, so you know exactly what you can afford to give at each stage. Remember that investors price rounds on a fully diluted basis: when they say 20%, they mean 20% of everything after conversions and the new pool. Model from that number, not from your current share count, or you will be surprised every time.

Keep it clean

A broken cap table is a documented deal-killer in life sciences. Diligence teams treat tangled equity structures, mismatched SAFE caps, and unclear ownership as a reason to pass, because the cleanup risk lands on the new investor.

Keep it simple: clean common stock for founders, standard vesting, a manageable investor count, and no thicket of conflicting convertible terms. The friction a messy cap table creates is exactly the friction you do not want when you are trying to close.

A Practical 12-Month Roadmap for Protecting Founder Equity in Biotech

Q1: Model the full cap table before raising a dollar (Months 1 to 3)

• Build your complete dilution model first. Map the anticipated rounds from pre-seed through a realistic exit, applying the stage benchmarks above. Identify what founder ownership looks like at Series C and at a plausible exit under your current plan.
• Identify the maximum non-dilutive capital available before the first priced round. Research SBIR Phase I opportunities at NIH, NSF, and DoD aligned with your program, and map disease-specific foundation grants in your area. Calculate how much science you can fund without dilution, and tie it to the milestone that justifies your target seed valuation.
• Audit your existing instruments. If you have SAFEs, confirm they are post-money, and calculate exactly what each converts to at your anticipated priced-round valuation.
• Model any anti-dilution exposure. Identify provisions in prior instruments and model the flat-round and down-round scenarios that would trigger them, so you understand your exposure before adding new investors.
• Set a target ownership floor for each stage. Decide the minimum founder ownership that keeps the eventual exit motivating, and use that floor to constrain how much dilution you accept at each round.

Q2: Maximize non-dilutive capital before the first equity round (Months 4 to 6)

• Submit your SBIR or STTR Phase I application to the agency best aligned with your work. NIH for therapeutics and diagnostics, NSF for computational and platform plays, DoD CDMRP for its specified disease areas. Apply early, since review cycles run several months.
• Apply for relevant foundation grants. Identify two or three disease-specific foundations and confirm their application windows, which are often annual.
• Use the non-dilutive runway to fund the milestone that justifies your seed valuation. The pre-money you can negotiate at seed is determined largely by the milestone you have passed before approaching investors.
• Build your comparable-deal database. Document three to five recent seed rounds in your area at a similar stage: pre-money, round size, lead investor. These become your valuation anchors.
• Draft your twelve-to-eighteen-month hiring plan in enough detail to justify a specific option pool size at the next priced round.

Q3: Negotiate your first equity round from a position of strength (Months 7 to 9)

• Approach seed investors only after the milestone that justifies your valuation is reached. A recent, de-risking data point creates urgency and reduces investor risk at the same time.
• Anchor your pre-money to your comparable deals rather than the investor’s opening number. Explain specifically how your milestone profile matches or beats the comps.
• Insist on a post-money SAFE with a single clean cap and no discount if the round is on convertibles.
• Negotiate pool size and timing. Present your hiring plan as the basis for sizing, and request a post-close pool. These two moves can reduce effective pre-round dilution by several points.
• Build your Series A target list in parallel, so your seed capital is funding the milestone that warms those relationships. Start by finding and qualifying the investors who fund companies at your next stage.

Q4: Set up the next round before the current one closes (Months 10 to 12)

• Update your cumulative model to reflect the closed seed round. Recalculate founder ownership at each future stage under the actual terms, and confirm the trajectory still clears your target floor.
• Start building a Series A investor pipeline before the seed capital is deployed. Series A closes typically happen twelve to eighteen months after seed, and the warm relationships that produce better terms take six to nine months to establish.
• Evaluate milestone tranching for the Series A. If your target is $20 million to $30 million, explore a first tranche of $10 million to $15 million tied to an IND filing, with the balance released on Phase I initiation.
• Model the venture debt option. With a signed seed round and a credible plan, venture debt may extend your runway to Series A without a new equity event, at warrant coverage that is far less dilutive than a bridge.

The Bottom Line

So, how much equity should biotech founders give investors? Around 15% to 25% per early priced round to the new investors, with the real answer shaped by the hidden mechanics and the biotech reality that you will raise more rounds over more years.

What to actually do:

• Know the benchmarks. Roughly 20% per early round to investors, with founders typically holding about 56% after seed and around 36% after Series A, lower in physical sciences like biotech.
• See the whole picture. Option pools, SAFEs, pro rata rights, anti-dilution, and liquidation preferences take more than the headline number, so model them all.
• Pull the biotech levers. Sequence non-dilutive capital first, raise only to the next milestone, use tranches, negotiate valuation and pool together, and raise from strength.
• Keep the cap table clean, because a messy one can sink a Series A on its own.

Dilution is not the enemy. Bad dilution is. Giving up 20% at seed to fund the IND-enabling work that justifies a strong Series A pre-money is excellent dilution.

Giving up 35% at seed at a $4 million pre-money before exhausting your SBIR options is bad dilution. The difference is not negotiating skill. It is preparation, sequencing, and an honest model of the full path before the first term sheet is signed.

Aim to own enough of a big enough outcome. Manage dilution as something you actively control round by round, not something that happens to you, and you will reach a liquidity event still holding a slice worth holding.

---

Explore My Services to see how valuation, investor targeting, and round strategy work together.

---

Frequently Asked Questions

---